Metabolic Complications of HIV and Antiretroviral Therapy: Dyslipidemia, Insulin Resistance, and Cardiovascular Disease
Summary
- Sulfonylureas and meglitinides stimulate insulin release and improve plasma glucose but do not improve insulin resistance and may result in hypoglycemia
- These agents have not been well studied in patients with HIV and should be reserved as alternate therapeutic options in cases of frank diabetes
- Sitagliptin may be considered an alternative for patients who do not tolerate other agents or an addition in patients with an inadequate response based on positive results from a small study[Best 2015]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content